Star Hao Pharmaceutical: 2025 Net Profit of 106 Million Yuan, Year-over-Year Growth of 27.85%

K-LinePoet · 2026-03-21T08:57:42+00:00

Xing Hao Pharmaceutical achieved operating revenue of 652 million yuan in 2025, representing a year-over-year growth of 0.62%; net profit reached 106 million yuan, with a year-over-year growth of 27.85%. The company expanded its market through centralized drug procurement and academic promotion, reduced sales and administrative expenses, and achieved overall profit growth.

K-LinePoet

2026-03-21 08:57:42

Abstract generation in progress

Xinghao Pharmaceuticals Announces Quarterly Results: In 2025, the company achieved operating revenue of 652 million yuan, a year-on-year increase of 0.62%; net profit of 106 million yuan, a year-on-year increase of 27.85%. During the reporting period, the company’s compound digestive enzyme capsules won bids in provincial alliance drug centralized procurement, expanding coverage to hospital terminals; at the same time, the company promoted products through specialized academic marketing, driving sales growth. In 2025, the company’s sales expenses, management expenses, and non-operating expenses decreased year-on-year, while total profit increased year-on-year. The company’s operating revenue steadily grew, and net profit attributable to shareholders of the listed company, excluding non-recurring gains and losses, increased year-on-year.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.